Ab­b­Vie shrugs off $134M cash deals, quit­ting a neu­ro R&D pact with Voy­ager Ther­a­peu­tics on vec­tor­ized an­ti­body treat­ments

It’s the end of the road for Voy­ager Ther­a­peu­tics’ col­lab­o­ra­tion with Ab­b­Vie on tau and al­pha-synu­cle­in vec­tor­ized an­ti­body de­vel­op­ment.

In two deals span­ning the last two years, Ab­b­Vie dropped more than $134 mil­lion up­front for Voy­ager’s pre­clin­i­cal R&D of vec­tor­ized an­ti­body treat­ments for dis­eases like Alzheimer’s and Parkin­son’s. But Voy­ager says Ab­b­Vie is walk­ing away now, with­out of­fer­ing an ex­pla­na­tion for why.

Omar Khwa­ja Voy­ager Ther­a­peu­tics

The first deal, penned in 2018, honed in on the po­ten­tial treat­ment of Alzheimer’s and oth­er neu­rode­gen­er­a­tive dis­eases by re­duc­ing tau pathol­o­gy, now a hot spot­light in the wake of nu­mer­ous amy­loid be­ta set­backs. Ab­b­Vie paid Voy­ager $69 mil­lion up­front to de­vel­op vec­tor­ized an­ti­bod­ies di­rect­ed against tau. Cam­bridge, MA-based Voy­ager had the op­por­tu­ni­ty to bag an­oth­er $155 mil­lion in pre­clin­i­cal and Phase I pay­ments, and $895 mil­lion in de­vel­op­ment and reg­u­la­to­ry mile­stones.

The fol­low­ing year, the col­lab­o­ra­tion ex­pand­ed to in­clude vec­tor­ized an­ti­bod­ies di­rect­ed at patho­log­i­cal species of al­pha-synu­cle­in for the treat­ment of Parkin­son’s dis­ease and oth­er synu­cle­inopathies. In that deal, Voy­ager pock­et­ed $65 mil­lion up­front, with the chance to earn an­oth­er $245 mil­lion in pre­clin­i­cal and Phase I pay­ments, $728 mil­lion in de­vel­op­ment and reg­u­la­to­ry mile­stones, and $500 mil­lion in com­mer­cial mile­stones.

Voy­ager’s one-time in­tra­venous in­jec­tions are de­signed to de­liv­er genes across the blood-brain bar­ri­er that en­code for the pro­duc­tion of  ther­a­peu­tic an­ti­bod­ies.

Fol­low­ing Voy­ager’s R&D, Ab­b­Vie had the op­tion to ad­vance one or more can­di­dates to IND-en­abling stud­ies and clin­i­cal de­vel­op­ment. Af­ter Phase I clin­i­cal de­vel­op­ment, the drug mak­er could have li­censed Voy­ager’s an­ti­body pro­grams for fur­ther clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion — though nei­ther pro­gram made it that far.

With the col­lab­o­ra­tion com­ing to an end, Voy­ager has re­gained full clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion rights to the ex­per­i­men­tal drugs de­vel­oped with Ab­b­Vie in the tau pro­gram. And Voy­ager says it’s free to pur­sue an­oth­er part­ner to de­vel­op its vec­tor­ized an­ti­body pro­grams for tau and al­pha-synu­cle­in.

“Through the tau and al­pha-synu­cle­in col­lab­o­ra­tions, we be­lieve we have made con­sid­er­able progress against tar­gets for neu­rode­gen­er­a­tive dis­eases with this nov­el ap­proach, re­in­forc­ing our en­thu­si­asm for its po­ten­tial to de­liv­er ther­a­peu­ti­cal­ly ef­fi­ca­cious lev­els of bi­o­log­ics to the brain and cen­tral ner­vous sys­tem,” said Omar Khwa­ja, Voy­ager’s CMO and head of R&D, in a pre­pared state­ment.

“We be­lieve our con­tin­ued work on dis­cov­ery and de­sign of nov­el AAV cap­sids with sub­stan­tial­ly im­proved blood-brain bar­ri­er pen­e­trance will al­so con­sid­er­ably broad­en the po­ten­tial of AAV-based gene ther­a­py, in­clud­ing vec­tor­ized an­ti­bod­ies or oth­er bi­o­log­ics, for the treat­ment of se­vere neu­ro­log­i­cal dis­eases,” he con­tin­ued.

Voy­ager’s stock $VY­GR fell about 15% to $9.62 af­ter-hours on Mon­day, af­ter the changes were an­nounced.

The com­pa­ny’s most ad­vanced drug in the pipeline is VY-AADC, an AAV-based gene ther­a­py cur­rent­ly en­rolled in a Phase II tri­al to treat Parkin­son’s dis­ease.

Qual­i­ty Con­trol in Cell and Gene Ther­a­py – What’s Re­al­ly at Stake?

In early 2021, Bluebird Bio was forced to suspend clinical trials of its gene therapy for sickle cell disease after two patients in the trial developed cancer. As company scientists rushed to assess whether there was any causal link between the therapy and the cancer cases, Bluebird’s stock value plummeted – as did those of multiple other biopharma companies developing similar therapies.

While investigations concluded that the gene therapy was unlikely to have caused cancer, investors and the public may be more skittish regarding the safety of gene and cell therapies after this episode. This recent example highlights how delicate the fields of cell and gene therapy remain today, even as they show great promise.

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

Back in early 2018 when Scott Gottlieb led the FDA, there was a moment when the agency seemed poised to release redacted complete response letters and other previously undisclosed data. But that initiative never gained steam.

Now, a growing chorus of researchers are finding that a dearth of public data on clinical trials and pharmaceuticals means industry and the FDA cannot be held accountable, two law professors from Yale and New York University write in an article published Wednesday in the California Law Review.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Novavax CEO Stanley Erck at the White House in 2020 (Andrew Harnik, AP Images)

As fears mount over J&J and As­traZeneca, No­vavax en­ters a shaky spot­light

As concerns rise around the J&J and AstraZeneca vaccines, global attention is increasingly turning to the little, 33-year-old, productless, bankruptcy-flirting biotech that could: Novavax.

In the now 16-month race to develop and deploy Covid-19 vaccines, Novavax has at times seemed like the pandemic’s most unsuspecting frontrunner and at times like an overhyped also-ran. Although they started the pandemic with only enough cash to last 6 months, they leveraged old connections and believers into $2 billion and emerged last summer with data experts said surpassed Pfizer and Moderna. They unveiled plans to quickly scale to 2 billion doses. Then they couldn’t even make enough material to run their US trial and watched four other companies beat them to the finish line.

FDA of­fers scathing re­view of Emer­gent plan­t's san­i­tary con­di­tions, em­ploy­ee train­ing af­ter halt­ing pro­duc­tion

The FDA wrapped up its inspection of Emergent’s troubled vaccine manufacturing plant in Baltimore on Tuesday, after halting production there on Monday. By Wednesday morning, the agency already released a series of scathing observations on the cross contamination, sanitary issues and lack of staff training that caused the contract manufacturer to dispose of millions of AstraZeneca and J&J vaccine doses.

Brad Bolzon (Versant)

Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

Brad Bolzon has an apology to offer by way of introducing a set of 3 new funds that together pack a $950 million wallop in new biotech creation and growth.

“I want to apologize,” says the Versant chairman and managing partner, laughing a little in the intro, “that we don’t have anything fancy or flashy to tell you about our new fund. Same team, around the same amount of capital, same investment strategy. If it ain’t broke, don’t fix it.”

But then there’s the flip side, where everything has changed. Or at least speeded into a relative blur. Here’s Bolzon:

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Emma Walmsley, GlaxoSmithKline CEO (Kevin Dietsch/Pool via CNP/Alamy)

Glax­o­SmithK­line hus­tles the 7th PD-1 past the fin­ish line with Jem­per­li. But how big will up­take be?

Everything came up sevens for GlaxoSmithKline on Thursday as the pharma notched the seventh PD-1 approval seven years after the first such drugs were OK’ed in Keytruda and Opdivo. But will it bring GSK good fortune?

The FDA granted accelerated approval to dostarlimab, to be branded Jemperli, to treat recurrent or advanced endometrial cancer in a specific subset of patients following platinum-based chemo. It’s a drug that came to GSK through its buyout of Tesaro, which it snapped up for $5.1 billion back in December 2018.

JP Gabriel, Ocugen

JP Gabriel watched from the bleach­ers as the pan­dem­ic raged. Now head of sup­ply chain at Ocu­gen, he's ready to bat

The world was in the middle of the most pressing public health risk his generation had ever seen, and JP Gabriel felt like he was sitting on the sidelines. As a VP of biologics and mRNA manufacturing at Ultragenyx, Gabriel watched from the sidelines as players like Pfizer/BioNTech and Moderna used mRNA tech to chase their own Covid-19 vaccines.

This month, Gabriel got the chance to get his hands dirty against the pandemic — but it won’t be with mRNA.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.

Sen. Patty Murray (D-WA) (Graeme Sloan/Sipa USA/Sipa via AP Images)

Sen­a­tors to NIH: Do more to pro­tect US bio­med­ical re­search from for­eign in­flu­ence

Although Thursday’s Senate health committee hearing was focused on how foreign countries and adversaries might be trying to steal or negatively influence biomedical research in the US, the only country mentioned by the senators and expert witnesses was China.

Committee chair Patty Murray (D-WA) made clear in her opening remarks that the US cannot “let the few instances of bad actors” overshadow the hard work of the many immigrant researchers in the US, many of which have won Nobel prizes for their work. But she also said, “There is more the NIH can be doing here.”

Jenny Rooke (Genoa Ventures)

Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem

When Jenny Rooke first heard of Zymergen back in 2014, she knew she was looking at something different and exciting. The Emeryville, CA biotech held the promise of blending biology and technology to solve a huge unmet need for cost-effective chemicals — of all things — and a stellar founding team to boot.

But back then, West Coast venture capitalists didn’t see in Zymergen the one thing they were looking for in a winning biotech: therapeutic potential. Rooke, however, saw an opportunity and made her bets. Seven years later, that bet is paying off in a big way.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.